Objetivo Injuries and degenerative diseases of the central nervous system constitute a bottleneck in medical and surgical practice for which no therapy currently exists. To ensure clinical translation, NeuroGraft is organised in three R&D Work-Packages. NeuroGraft will develop functionalised cell seeded bioartificial organs, specifically spinal cord conduits for transplantation, incorporating a potent immunomodulatory cytokine (IL37) to target the initial inflammatory response to increase the survival and therapeutic efficacy of transplanted mesenchymal cells and the expression of potent neuro-regulatory molecules for enhanced functional nerve regeneration in the central nervous system.This exciting concept will be realised through the NeuroGraft consortium, consisting of one academic and four industrial partners (all SMEs), across four countries, with distinct synergistic expertise (including regulatory expertise) to develop cell seeded functionalised bioartificial organs as valuable solutions towards spinal cord repair. Regulatory advice is incorporated at an early stage in the development cycle, to facilitate the translation of the novel bioartificial devices developed, to the market in as short a timeframe as possible. The NeuroGraft consortium will validate the safety, efficacy and biodistribution of the functionalised bioartificial organs developed in a pre-clinical model of spinal cord under GLP conditions. Full Quality Assurance reports will be completed towards CE Mark regulatory approval of the medical device for spinal cord repair. These studies will facilitate progression to clinical trials of the technology (post project) and the development of a marketable product within 6 years of the completion of the NeuroGraft project. Intellectual property will be patented ensuring that SME’s have veto rights on commercial route for exploitation. An extensive business plan outlining detailed valorisation plan is presented. Ámbito científico natural sciencesbiological sciencesneurobiologymedical and health sciencesclinical medicinetransplantation Programa(s) FP7-HEALTH - Specific Programme "Cooperation": Health Tema(s) HEALTH.2012.1.4-2 - Medical technology for transplantation and bioartificial organs Convocatoria de propuestas FP7-HEALTH-2012-INNOVATION-2 Consulte otros proyectos de esta convocatoria Régimen de financiación CP-FP - Small or medium-scale focused research project Coordinador UNIVERSITY OF GALWAY Aportación de la UE € 1 347 138,24 Dirección UNIVERSITY ROAD H91 Galway Irlanda Ver en el mapa Región Ireland Northern and Western West Tipo de actividad Higher or Secondary Education Establishments Contacto administrativo Mari Vahey (Ms.) Enlaces Contactar con la organización Opens in new window Sitio web Opens in new window Coste total Sin datos Participantes (4) Ordenar alfabéticamente Ordenar por aportación de la UE Ampliar todo Contraer todo ASHLAND SPECIALTIES IRELAND LIMITED Irlanda Aportación de la UE € 797 383,60 Dirección NATIONAL SCIENCE PARK, BUILDING V, DUBLIN ROAD, PETITSWOOD N91 F6PD MULLINGAR, WESTMEATH Ver en el mapa Tipo de actividad Private for-profit entities (excluding Higher or Secondary Education Establishments) Contacto administrativo Colm O'dowd (Dr.) Enlaces Contactar con la organización Opens in new window Sitio web Opens in new window Coste total Sin datos STEMMATTERS, BIOTECNOLOGIA E MEDICIINA REGENERATIVA SA Portugal Aportación de la UE € 1 053 415,50 Dirección PARQUE DE CIENCIA E TECNOLOGIA AVEPARK ZONA INDUSTRIAL DA GANDRA 4805-017 Barco Gmr Ver en el mapa Región Continente Norte Ave Tipo de actividad Private for-profit entities (excluding Higher or Secondary Education Establishments) Contacto administrativo Celia Pinto (Dr.) Enlaces Contactar con la organización Opens in new window Sitio web Opens in new window Coste total Sin datos NAMSA Francia Aportación de la UE € 513 550,00 Dirección CHEMIN DE L ISLON 115 38670 CHASSE SUR RHONE Ver en el mapa Región Auvergne-Rhône-Alpes Rhône-Alpes Isère Tipo de actividad Private for-profit entities (excluding Higher or Secondary Education Establishments) Contacto administrativo Eleonore Puissant (Dr.) Enlaces Contactar con la organización Opens in new window Sitio web Opens in new window Coste total Sin datos OBELIS SA Bélgica Aportación de la UE € 499 887,50 Dirección BOULEVARD GENERAL WAHIS 53 1030 Bruxelles / Brussel Ver en el mapa Región Région de Bruxelles-Capitale/Brussels Hoofdstedelijk Gewest Région de Bruxelles-Capitale/ Brussels Hoofdstedelijk Gewest Arr. de Bruxelles-Capitale/Arr. Brussel-Hoofdstad Tipo de actividad Private for-profit entities (excluding Higher or Secondary Education Establishments) Contacto administrativo Doram Elkayam (Mr.) Enlaces Contactar con la organización Opens in new window Sitio web Opens in new window Coste total Sin datos